CORONA Remedies posts double-digit growth in Q2, H1 FY26; PAT surges up to 35%

The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half

Cupid reports record Q3, eyes GCC expansion with Saudi FMCG facility

Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity

SN Bioscience’s SNB-101 wins FDA orphan drug designation for gastric cancer

The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38

Teva moves within reach of investment grade as S&P upgrades credit rating & Moody’s positive

China approves first-in-class TGCT drug, marking global first for pimicotinib

Cupid reduces promoter pledged stake to 20%

This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence

Soligenix publishes promising Phase 2a data for SGX945 in Behcet's Disease

SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers

Astellas & Pfizer report breakthrough Phase 3 results in muscle-invasive bladder cancer

The combination also outperformed chemotherapy on another important secondary endpoint

AstraZeneca wins EU nod for self-administered lupus drug Saphnelo

Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion

FDA nods spotlight precision oncology platforms as market surges towards $212 billion by 2034

The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034